Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update

May 25, 2012 1:21 PM EDT Send to a Friend
Get Alerts TEVA Hot Sheet
Price: $58.00 +2.38%

Rating Summary:
    19 Buy, 13 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade TEVA Now!
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Teva Pharma (NASDAQ: TEVA) price target of $42.00.

Analyst, Douglas D. Tsao, said, "We are lowering our FY12 EPS estimate to $5.33 (from $5.57) after the company lowered guidance yesterday morning as part of a business update provided by newly-minted CEO Jeremy Levin. The timing was a bit of a surprise, but the takedown in expectations was largely anticipated after TEVA's 1Q showed softness. Management lowered its '12 EPS range to $5.30-$5.40 (cons $5.59) versus the previous $5.48-$5.68 (consensus at $5.59), with '12 revenues declining to $20Bn-$21bn versus previous $22bn."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $38.69 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Barclays

Add Your Comment